KOSDAQChemicals318060

Graphy

₩9,170▲ 1.55%2026-11-18 close
Market Cap
₩102.7B
Turnover
₩500M
Volume
50K
Shares out.
11.2M
PER
—
PBR
3.2×
EPS
-₩1,353
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Overseas expansion vs. ongoing operating losses

Graphy is widening its overseas revenue base, but operating losses have continued for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026, making the timing of a return to profit the key checkpoint.

  1. 1

    Revenue rose 27.3% to KRW 20.5 billion in 2025, but the operating loss widened to KRW 11.1 billion.

  2. 2

    Third-quarter 2026 revenue fell 11.1% year on year to KRW 3.06 billion, and the operating loss widened to KRW 5.33 billion.

  3. 3

    In a shareholder letter in early November 2026, the company acknowledged delays in its U.S. production base and order expansion, and said it will prioritize profitability over top-line growth.

  4. 4

    Analyst data showing overseas sales above 80% of revenue and a second-quarter gross margin of 77.8% point to a high-margin structure, while selling and administrative costs continue to weigh on profit.

  5. 5

    The next checkpoints are the preliminary fourth-quarter 2026 results and the full-year 2026 operating margin in the annual report.

02

Business structure

Graphy develops and sells shape memory aligners (SMA) built on its shape memory material technology, making it a dental solutions company. Its oligomer design and synthesis technology forms the basis of its materials, and brokers describe it as having commercialized the world's first shape memory clear aligner.

The company listed on KOSDAQ in August 2025. Revenue comes from SMA finished products, shape memory materials and equipment, and in early 2026 the company said growth would be driven by higher materials and equipment sales.

The core sales model is an in-house system in which dental clinics print the products themselves; one brokerage noted that more than 100 users in Japan run this system. Overseas sales account for more than 80% of revenue, supported by more than 150 distribution channels across over 90 countries.

In Europe, supply is expanding through the German contract manufacturer Medentis, while in the United States the company is testing with dental service organizations after setting up a local subsidiary. Reports also noted that Graphy obtained official U.S. FDA clearance, which is cited as a driver of global expansion.

Coverage of third-quarter 2026 results also referred to the completion of the acquisition of a digital dental company.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩3.4B-₩3.7B−108.2%
2025Q4₩10.4B-₩1.2B−11.2%
2026Q1₩3.4B-₩3.2B−95.1%
2026Q2₩6.3B-₩3.7B−58.8%
2026Q3₩3.1B-₩5.3B−174.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩16.1B-₩9.2B-₩32.7B−56.9%−846.8%470.0%
2025₩20.5B-₩11.1B-₩11.7B−53.8%−55.4%88.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a full-year basis from the audited filings, revenue rose 27.3% from KRW 16.1 billion in 2024 to KRW 20.5 billion in 2025, and the company described this as its highest annual revenue on record.

Over the same period the operating loss widened from KRW 9.17 billion to KRW 11.1 billion, moving the operating margin from -56.9% to -53.8%. Higher research and development and selling and administrative expenses were cited as reasons losses grew despite higher sales.

The net loss attributable to controlling shareholders narrowed from KRW 32.7 billion to KRW 11.7 billion, and the net loss including non-controlling interests shows the same figures. The filings show losses in both 2024 and 2025.

The debt ratio fell from 470.0% at the end of 2024 to 88.6% at the end of 2025, and total equity of KRW 21.1 billion at the end of 2025 is entirely attributable to controlling shareholders. Operating cash flow worsened from KRW -9.62 billion in 2024 to KRW -15.1 billion in 2025.

Quarterly revenue peaked at KRW 10.4 billion in the fourth quarter of 2025, fell to KRW 3.35 billion in the first quarter of 2026, recovered to KRW 6.28 billion in the second quarter, and dropped again to KRW 3.06 billion in the third quarter.

One brokerage noted that fourth-quarter results can look relatively strong because clinic adoption decisions tend to concentrate toward year-end. Third-quarter 2026 operating loss of KRW 5.33 billion was larger than the KRW 3.72 billion loss in the third quarter of 2025, and revenue fell 11.1% year on year.

Coverage in August 2026 cited a second-quarter consolidated gross margin of 77.8%, with SMA finished-product shipments up 98.9% year on year. A brokerage attributed continued losses partly to a selling and administrative expense ratio of 147.8% in the first half of 2025.

The net loss attributable to controlling shareholders over the most recent four quarters totals KRW 15.5 billion.

05

Industry analysis

Demand for clear aligners depends on dental clinics deciding to adopt the system, and the in-house model builds up materials usage after each adoption. One brokerage analyst noted that North America accounts for 45% of the orthodontic market and that revenue could begin ramping in the second half of the year.

Another analyst saw high growth continuing not only in Europe and North America but also in the Middle East, Africa and Latin America. On the earnings side, one analysis argued that subsequent materials usage matters more than equipment sales.

For China, the company's early-2026 plan called for completing SMA certification and holding a local launch event in June 2026. Industry commentary suggested that directly printed SMA could become a new standard in China's clear aligner market.

The company emphasizes a recurring revenue structure driven by repeat materials orders. This structure depends on clinic adoption speed, so quarterly revenue can swing sharply.

Even if the end market grows quickly, the timing of conversion to revenue depends on the sequence of certification, distribution partnerships and local production.

06

Outlook

Early in 2026 the company set full-year targets of revenue above KRW 40 billion and a shift to operating profit. However, operating losses were reported in each of the first, second and third quarters of 2026, and third-quarter revenue fell year on year.

In a FnGuide consensus compiled in May 2026, third-quarter 2026 revenue was estimated at KRW 8.8 billion, while the reported third-quarter figure was KRW 3.06 billion.

In a shareholder letter in early November 2026, the company acknowledged that its U.S. production base and key distribution orders were delayed, and that the three-way partnership after its acquisition had not delivered results as quickly as hoped.

The company said it will prioritize real sales growth and profitability over expansion of the top line. It plans to secure visible overseas results starting in November, with European certification and global order expansion as tasks, and coverage framed a fourth-quarter revenue recovery as the key test.

In late 2025 a brokerage expected that the combination of domestic in-house adoption, overseas expansion and higher materials usage would make an earnings improvement clearer from 2026. That view dates from the time it was published and should be checked against the reported results through the third quarter.

The next checkpoints are whether the preliminary fourth-quarter 2026 results show a revenue recovery, and whether the full-year 2026 operating margin and operating cash flow in the annual report improve. Progress on the overseas production base and European certification will be checked alongside quarterly results.

07

Valuation

PER
—
PBR
3.2×
ROE
-53.9%
EPS
-₩1,353
BPS
₩3,153
Dividend per share
₩0

Because the company has posted net losses over the most recent four quarters, a price-to-earnings ratio cannot be calculated, so earnings-based multiples do not provide a meaningful comparison. The price-to-book ratio sits at a high multiple, meaning the share price is well above book value per share.

Total equity at the end of 2025 was KRW 21.1 billion, so book value is the main anchor while losses continue. The company does not currently pay dividends, so dividend-based valuation comparisons do not apply.

Early-2026 brokerage estimates assumed a turn to profit, but operating losses have continued through the third quarter, so the point at which earnings-based metrics become meaningful depends on whether full-year operating profit turns positive.

The key items to check are the preliminary fourth-quarter 2026 results and the operating profit in the 2026 annual report. Comparisons based on revenue and assets remain possible, but their interpretation is limited to the pace of business growth and whether cash flow improves.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Overseas revenue base and distribution network

Overseas sales exceed 80% of revenue, supported by more than 150 distribution channels across over 90 countries, so the business does not rely on the domestic market alone.

Supply in Europe is expanding through contract manufacturing with Medentis, and the U.S. has moved into testing with dental service organizations after forming a local subsidiary. A wider network can add in-house clinics, which supports the base for top-line growth.

High-margin materials and recurring revenue

Coverage in August 2026 cited a second-quarter consolidated gross margin of 77.8%, and SMA finished-product shipments rose 98.9% year on year. The company said it is strengthening a recurring revenue base driven by repeat materials orders.

If selling and administrative costs decline, the high gross margin could translate into better operating results.

Certification progress and China plans

Reports cited official U.S. FDA clearance, and European certification was listed as a company task. In China, the company announced plans to complete Class II medical device certification and hold a local launch. If regulatory approvals convert into local sales, overseas revenue could rise further.

09

Bear factors

Continued losses and a wider operating deficit

Operating losses have continued for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026. The third-quarter 2026 operating loss of KRW 5.33 billion was larger than in the third quarter of 2025, and revenue fell 11.1% year on year.

The net loss attributable to controlling shareholders over the last four quarters totals KRW 15.5 billion, and the filings do not yet show a turn to profit.

Delays in overseas execution

In a shareholder letter in early November 2026, the company acknowledged delays in its U.S. production base and in expanding orders with key distribution channels. The three-way partnership after the acquisition also fell short of expectations.

Against a May 2026 consensus estimate of KRW 8.8 billion for third-quarter revenue, the reported figure was KRW 3.06 billion.

Selling costs and cash flow pressure

A brokerage pointed out that the selling and administrative expense ratio was still high at 147.8% in the first half of 2025. Even with a high gross margin, profit recovery could be slower if selling costs and cash outflows do not decline.

10

Risk factors

Overseas production and distribution execution

If the U.S. production base and expanded distribution orders remain delayed, the timing of overseas revenue targets will slip. Progress on European certification and the China launch schedule also needs to match company plans.

Because overseas sales dominate revenue, local regulation or partner performance can feed directly into results.

Financial position and cash flow

Operating cash outflow widened to KRW -15.1 billion in 2025, and total equity at the end of 2025 was KRW 21.1 billion. If losses continue, the equity base could shrink, so cash generation must be watched alongside profit.

The debt ratio fell to 88.6% at the end of 2025, but without a change in the loss structure, the financial cushion could change.

Quarterly volatility and seasonality

Revenue jumped to KRW 10.4 billion in the fourth quarter of 2025 and then fell to KRW 3.35 billion in the first quarter of 2026. Because clinic adoption decisions cluster toward year-end, quarterly results can concentrate in a few periods. A single quarter is therefore a limited basis for judging the trend.

11

What to watch next

  1. Late January 2027 (expected)

    Preliminary fourth-quarter 2026 results. Check whether the revenue recovery the company flagged appears and whether the operating loss narrows. The timing follows last year's pattern, when fourth-quarter preliminary results were released in late January.

  2. After November 2026 (timing set by the company)

    Check whether visible results emerge in overseas business, including U.S. production operations, European certification and expanded global orders. Compare the timetable in the shareholder letter with actual outcomes and their effect on later results.

  3. End of March 2027 (annual report deadline)

    Review full-year 2026 revenue, operating margin and operating cash flow in the annual report. Whether full-year operating profit turns positive is the central point for interpreting valuation.

  4. Late April 2027 (expected)

    Preliminary first-quarter 2027 results. The timing follows the 2026 pattern, when first-quarter results were disclosed in late April. Check whether the annual profit-turn plan shows up in quarterly results.

12

Overall view

Graphy's revenue rose 27.3% to KRW 20.5 billion in 2025, but its operating loss widened to KRW 11.1 billion. Operating losses continued in all three quarters of 2026 through the third quarter, and third-quarter revenue also fell year on year.

Its strengths are its overseas revenue base, its distribution network and a materials-driven structure with high gross margins. Its weaknesses are the acknowledged delays in the U.S. production base and three-way partnership, the selling cost burden and negative operating cash flow.

The company said it has shifted priority to profitability over expansion, but the effect has not yet clearly appeared in quarterly results. The next checkpoints are the preliminary fourth-quarter 2026 results and the full-year operating margin and cash flow in the 2026 annual report.

Valuation interpretation depends on when earnings-based metrics become meaningful, that is, whether the company turns profitable. This report is for information only and does not include a buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. kbthink.com
  2. m.thinkpool.com
  3. marketin.edaily.co.kr
  4. buffettlab.co.kr
  5. news1.kr
  6. comp.fnguide.com
  7. fnnews.com
  8. news.nate.com
  9. news.nate.com
  10. dentalarchive.tv
  11. theguru.co.kr
  12. g-enews.com
  13. news.nate.com
  14. g-enews.com
  15. wowglobal.co.kr
  16. edata.ekn.kr
  17. g-enews.com
  18. indexbox.io

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis